Market Access Capping the cost of insulin: altruistic or strategic? The price of insulin has become one of the most talked about issues across the pharma industry.
News Twitter trolls, Musk's changes tank stocks for Lilly, other ... Elon Musk's Twitter takeover has been nothing if not tumultuous, and that tumult hit home for pharma Thursday, when an account impersonating Eli Lilly and Company - taking advantage of lax
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face